# Methylation Sciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/methylation-sciences

- Industry: Biotechnology
- Headquarters: Burnaby, Canada
- Website: www.methylationsciences.com
- Total disclosed funding: $19M
- Latest round: Series A (Sep 29, 2011)
- Investors on record: 3

## About

Methylation Sciences Inc. specializes in advancing therapeutic solutions through innovative research in DNA methylation and epigenetics, focusing on the development of novel therapies for various health conditions.Founded in 2007, Methylation Sciences Inc. is based in Burnaby, Canada, and is dedicated to the study of DNA methylation's impact on health. The company has undergone strategic pivots but maintains its focus on developing innovative therapeutic solutions. The latest funding round occurred in October 2016, where Quark Ventures led a USD 30 mn venture financing, raising the total capital to USD 30 mn. The firm has engaged in three deals since its inception.Methylation Sciences Inc. specializes in developing therapeutic solutions targeted at understanding and manipulating DNA methylation processes. Their research aims to create innovative treatments for various health conditions, thereby advancing the field of personalized medicine through a deeper understanding of epigenetics.Methylation Sciences Inc. generates revenue primarily through its research and development initiatives, focusing on the creation of therapies derived from its findings in DNA methylation. The company’s income structure is based on partnership agreements and potential licensing of its innovative therapies, contributing to a stable revenue model as it progresses through its research phases.Methylation Sciences Inc. plans to enhance its research portfolio by launching new therapeutic products focusing on DNA methylation mechanisms in the coming years. The firm aims to expand its market presence, specifically targeting North American and European markets by 2025. Recent funding from the USD 30 mn venture financing will support these initiatives, facilitating further research and development efforts to bring innovative therapies to market.

## Funding rounds

- Series A, Sep 29, 2011, $19M — Inventages Venture Capital, GrowthWorks Capital, BC Advantage Funds

## Investors

- Inventages Venture Capital (https://capitalatlas.ai/funds/inventages-venture-capital) — Series A
- GrowthWorks Capital (https://capitalatlas.ai/funds/growthworks-capital) — Series A
- BC Advantage Funds (https://capitalatlas.ai/funds/bc-advantage-funds) — Series A